SureTrader Advertisement PRTC
Home > Boards > Free Zone > Health and Sciences > Biotech Values

Highlights from AGN’s 1Q11 CC:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 620
Posts 92,673
Boards Moderated 29
Alias Born 09/05/02
160x600 placeholder
Axa Sells U.k. Pensions And Direct Protection Businesses To Phoenix
AXA has agreed to sell its investment, pensions and direct protection businesses in the U.K. to Phoenix Group as part of the French insurerstrategy to exit some parts of Europe and invest in faster growing markets.
More Top Equities Stories Of The Day
Google Wins Software Case -- WSJ
Snapchat Valuation Nears $18 Billion
Facebook and Microsoft To Build Fiber Optic Cable Across Atlantic
Troubled Online Lender Seeks Financing -- WSJ
Civil Antitrust Claims Reinstated Against 16 Banks in Libor Case -- 2nd Update
India to Require Apple to Use Local Sourcing
Valeant Rejected Joint Takeover Approach From Takeda, TPG
Shire Shareholders Approve $32 Billion Baxalta Merger; Deal Expected to Close June 3
DewDiligence Member Level  Wednesday, 05/04/11 03:11:09 PM
Re: DewDiligence post# 114167
Post # of 201622 
Highlights from AGN’s 1Q11 CC:

• 2011 non-GAAP EPS guidance raised by $0.02 to a range $3.56-3.62 (+14% YoY).

• Botox: $365M, +9% YoY in local currencies. Dysport, the main competitor, remains stuck at a 17% procedure share in US cosmetic indications and a de minimis share in US medical indications share (#msg-62706265, #msg-49695053). Xeomin’s US market share in also de minimis. Worldwide in all indications, Botox has an 80% market share.

• Juvederm franchise: $88M, +47% YoY in local currencies, due in part to inventory stocking for a promotional program aimed at patients who used Botox and Juvederm.

• Latisse: $25M, +34% YoY, +47% QoQ in local currencies due to some inventory stocking. Although 1Q11 was on track with AGN’s forecast of 2011 sales of $100M, Latisse is clearly not ramping up as quickly as I expected when the product was approved in late 2008 (#msg-34424441).

• Only weak product was LapBand: $52M, -16% YoY in local currencies; however, LapBand retained a 73% global market share in the category. (JNJ has the rest.)

• Sales of all AGN products in Latin America increased 32% YoY in dollars, thanks in part to the stronger Brazilian Real.

15% of AGN’s overall sales are in emerging markets; CEO, David Pyott thinks this will go to 25-30% in the next five years.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist